NCT05768932 2025-10-15
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
Phase 1 Recruiting
SillaJen, Inc.
Instituto do Cancer do Estado de São Paulo
Blokhin's Russian Cancer Research Center
Hanmi Pharmaceutical Company Limited